Introduction
============

Osteosarcoma (OS) is most prevalent in children and young adults, and it is the 8th most common form of childhood cancer ([@b1-ijmm-40-05-1357]). Despite the success of chemotherapy for OS, it is still associated with one of the lowest survival rates for pediatric cancer. Even after the complete removal of the primary tumor, the metastasis of OS contributes to the poor prognosis of most patients.

With the progress being made in the elucidation of the molecular mechanisms responsible for tumor development, many researchers have tried to unveil the molecular mechanisms underlying the metastasis of OS, which may provide novel therapeutic targets or diagnostic biomarkers. The PI3K/Akt signaling pathway ([@b2-ijmm-40-05-1357],[@b3-ijmm-40-05-1357]) and NF-κB pathway ([@b4-ijmm-40-05-1357],[@b5-ijmm-40-05-1357]) have been implicated in the promotion of OS metastasis. Notch signaling has been identified to play a critical role in the invasion and metastasis of OS ([@b6-ijmm-40-05-1357]). The HIF-1α/CXCR4 pathway has also been shown to promote the hypoxia-induced metastasis of human OS cells ([@b7-ijmm-40-05-1357]).

Several genes implicated in OS metastasis have been disclosed, such as ezrin ([@b8-ijmm-40-05-1357],[@b9-ijmm-40-05-1357]). It has been reported that β4 integrin promotes OS metastasis and interacts with ezrin ([@b10-ijmm-40-05-1357]). Moreover, aldolase A ([@b11-ijmm-40-05-1357]), cyclooxygenase-2 ([@b12-ijmm-40-05-1357]), and insulin-like growth factor binding protein 5 ([@b13-ijmm-40-05-1357]) have been shown to be involved in the metastasis of OS. However, knowledge of the molecular mechanisms responsible for the development of OS is limited. There is still a lack of effective targeted therapies and tumor-related biomarkers. Nevertheless, current knowledge is insufficient to markedly improve the outcomes of patients with metastatic OS.

Gene expression profiling has been utilized to identify critical genes associated with metastasis ([@b14-ijmm-40-05-1357]--[@b16-ijmm-40-05-1357]), as well as to develop novel treatments ([@b17-ijmm-40-05-1357]). In order to identify novel and reliable genes associated with metastasis, a meta-analysis of gene expression profiles was performed in the present study. Differentially expressed genes (DEGs) between metastatic and non-metastatic OS were revealed, followed by protein-protein interaction (PPI) network analysis. The featured genes were disclosed via support vector machine (SVM) classification. Moreover, an SVM classifier was acquired and validated.

Materials and methods
=====================

Gene expression profiles and pre-treament
-----------------------------------------

Gene expression datasets were retrieved from Gene Expression Omnibus (GEO) using the key words \'osteosarcoma\', \'metastasis\', and \'*Homo sapiens*\' by the end of April 28th, 2016. Five datasets ([Table I](#tI-ijmm-40-05-1357){ref-type="table"}) that met the following criteria were collected: i) gene expression data; ii) OS; and iii) information about metastasis was described.

The gene expression datasets GSE14359 and GSE14827 were acquired with Affymetrix platforms. Thus, background correction and normalization were performed with package \'affy\' of R. Missing values were filled with the median method. Background correction was carried out using the MSA method. Normalization was achieved with the quantiles method.

For the other 3 gene expression datasets, probes were then mapped into genes. Probes corresponding to the same gene were averaged as the final expression value of the gene. Normalization was performed with package limma ([@b18-ijmm-40-05-1357]) of R.

Screening of DEGs
-----------------

Prior to meta-analysis, the 5 gene expression datasets were assessed using package MetaQC ([@b19-ijmm-40-05-1357]), as well as principal component analysis (PCA) and standardized mean rank (SMR). The following criteria were applied in the assessment: i) internal quality control (IQC), homogeneity test of gene expression profiles among datasets; ii) external quality control (EQC), homogeneity test of gene expression profiles with pathway database; iii) accuracy quality control (AQC), accuracy of featured genes (AQCg) or pathways (AQCp); and iv) consistency quality control (CQC), consistency in ranking of featured genes (CQCg) or pathways (CQCp).

DEGs were screened out using the MetaDE.ES from package MetaDE. This method first tested the heterogeneity of gene expression value in various platforms with three statistic parameters: τ^2^, Q-value and Qpval. It then tested differential expression of genes between different groups with statistic parameters P-value. To ensure the homogeneity of featured genes, τ^2^=0, Qpval\>0.05 and P\<0.05 were set as the cut-offs.

Construction of protein-protein interaction (PPI) network
---------------------------------------------------------

The PPI information was downloaded from the database of protein, chemical, and genetic interactions (BioGRID, <http://thebiogrid.org/>) ([@b20-ijmm-40-05-1357]), Human Protein Reference Database (HPRD, <http://www.hprd.org/>) ([@b21-ijmm-40-05-1357]) and Database of Interacting Proteins (DIP, <http://dip.doe-mbi.ucla.edu/dip/Main.cgi>) ([@b22-ijmm-40-05-1357]). The protein products of the DEGs were mapped into the whole network and the PPI network for the DEGs was then acquired. The network was then visualized with Cytoscape ([@b23-ijmm-40-05-1357]).

Calculation of betweenness centrality (BC)
------------------------------------------

The featured genes were screened out from the DEGs using BC, which reflected hubness of the node in the PPI network. The BC was calculated as follows: where *σ~st~* is the shortest path from *s* to *t*; *σ~st~*(*ν*) is the number of the shortest path from *s* to *t* passing through node *V*; BC score is between 0 and 1, and the greater BC score indicates the higher degree of hubness.

Training and validation of SVM classifier
-----------------------------------------

The dataset GSE21257 was selected as the training set. Genes were ranked based upon the BC value and top 10 genes were selected out to train the SVM classifier. An increment of 10 genes were added into the classifier until the metastatic OS could be totally separated from non-metastatic OS. These DEGs were regarded as featured genes. Two-way clustering of sample and gene expression was applied on the featured genes and the result was visualized with a heatmap. The other 3 gene expression datasets were used as the validation set. Sensitivity (Se), specificity (Sp), positive predictive value (PPV), negative predictive value (NPV) and the area under the curve (AUC) were calculated to evaluate the SVM classifier.

Pathway enrichment analysis
---------------------------

Gene Ontology (GO) biological pathways and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways related to featured genes were identified using runHyperGO and runHyperKEGG from package EMA of R. The significance was calculated using Fisher\'s exact test as follows: where N is the total number of gene; M is the number of gene in the pathway; K is the number of featured gene.

Results
=======

DEGs
----

Quality control test was applied on the 5 gene expression datasets and the results are listed in [Table II](#tII-ijmm-40-05-1357){ref-type="table"}. As shown in the PCA result ([Fig. 1](#f1-ijmm-40-05-1357){ref-type="fig"}), the dataset GSE9508 far deviated from the other 4 datasets, which was assessed as poor quality. Thus, the dataset GSE9508 was excluded from the following analysis.

According to the criteria described above, a total of 353 DEGs were identified from the 4 datasets. The top 10 DEGs (ranked by P-value) are listed in [Table III](#tIII-ijmm-40-05-1357){ref-type="table"}, including chromosome 13 open reading frame 18 (*C13orf18*), activating transcription factor 3 (ATF3), cadherin 5 (*CDH5*), epoxide hydrolase 2 (EPHX2), cadherin 3 (*CDH3*), ectonucleoside triphosphate diphosphohydrolase 5 (*ENTPD5*), forkhead box A1 (FOXA1), ephrin B2 (*EFNB2*), bromo adjacent homology domain containing 1 (*BAHD1*) and chromosome 10 open reading frame 76 (*C10orf76*).

PPI network
-----------

Non-DEGs interacting with no less than 5 DEGs were also included in the PPI network. Finally, a PPI network containing 164 nodes and 272 edges was obtained ([Fig. 2](#f2-ijmm-40-05-1357){ref-type="fig"}). The distribution of degree is shown in [Fig. 3](#f3-ijmm-40-05-1357){ref-type="fig"}. Most genes (168 genes) showed a small degree (Log transformed degree \<1), while only 2 genes had a Log transformed degree of \>4. Therefore, similar to most biological networks, this PPI network exhibited scale-free property. These genes with a high degree were hub genes and may thus play important roles in the development of diseases.

Featured genes
--------------

BC was calculated for each node and the top 10 genes are listed in [Table IV](#tIV-ijmm-40-05-1357){ref-type="table"}. These were estrogen receptor 1 (*ESR1*), E1A binding protein p300 (*EP300*), tumor protein p53 (*TP53*), SMAD family member 3 (*SMAD3*), epidermal growth factor receptor (*EGFR*), fibronectin 1 (*FN1*), SRC proto-oncogene, non-receptor tyrosine kinase (*SRC*), protein kinase Cα (*PRKCA*), DEAD-box helicase 5 (*DDX5*) and erythropoietin receptor (*EPOR*).

SVM classifier
--------------

Top genes were selected out to train the SVM classifier with the dataset GSE21257. As shown in [Fig. 4A](#f4-ijmm-40-05-1357){ref-type="fig"}, the accuracy increased from 75 to 100%, while more genes were included in the classifier. The accuracy reached 100%, while the top 100 genes (containing 64 DEGs; data not shown) were included in the classifier. Therefore, the top 64 featured genes (data not shown) were selected to construct the SVM classifier. The classifier could separate metastatic OS from non-metastatic OS in the dataset GSE21257 ([Fig. 4B](#f4-ijmm-40-05-1357){ref-type="fig"}).

Hierarchical clustering was performed for the 53 samples from the training dataset GSE21257 using the 64 featured genes and the results are shown in [Fig. 5](#f5-ijmm-40-05-1357){ref-type="fig"}. The 64 featured genes could well distinguish metastatic OS samples from non-metastatic OS samples.

The SVM classifier was validated using the other 3 independent datasets GSE32981, GSE14827 and GSE14359. The accuracies were high in all datasets, with a prediction accuracy of 100% in dataset GSE32981 ([Fig. 6A](#f6-ijmm-40-05-1357){ref-type="fig"}) and GSE14359 ([Fig. 6C](#f6-ijmm-40-05-1357){ref-type="fig"}) and 92.6% in dataset GSE14827 ([Fig. 6B](#f6-ijmm-40-05-1357){ref-type="fig"}). Two non-metastatic OS samples were predicted wrong as metastatic samples in dataset GSE14827. The accuracy, sensitivity, specificity, PPV, NPV and AUC are listed in [Table V](#tV-ijmm-40-05-1357){ref-type="table"}.

Over-represented biological pathways
------------------------------------

A total of 11 GO biological pathways ([Fig. 7](#f7-ijmm-40-05-1357){ref-type="fig"}) and 5 KEGG pathways ([Table VI](#tVI-ijmm-40-05-1357){ref-type="table"}) were identified in the 64 featured genes. Some pathways were significantly over-represented in the featured genes, such as regulation of cell proliferation, regulation of apoptosis, pathways in cancer, regulation of actin cytoskeleton and the TGF-β signaling pathway.

Discussion
==========

Four gene expression datasets were included in this meta-analysis. A total of 353 DEGs were identified and a PPI network including 164 nodes, as well as 272 edges was constructed. The top 64 featured genes ranked by BC were included in the SVM classifier. The prediction accuracies for the 4 datasets were 100, 100, 92.6 and 100%, respectively. Pathways, such as regulation of cell proliferation, regulation of apoptosis, pathways in cancer, regulation of actin cytoskeleton and the TGF-β signaling pathway were significantly over-represented in the 64 featured genes. These pathways were closely associated with cancer and cell mobility.

In the featured genes, some have been implicated in the metastasis of OS. CD44 molecule (*CD44*) is a cell-surface glycoprotein involved in cell-cell interactions, cell adhesion and migration. It participates in a wide variety of cellular functions, including metastasis. Kim *et al* reported that the expression of CD44 isoforms correlated with the metastatic potential of OS ([@b24-ijmm-40-05-1357]). Zhao *et al* found that miR-34a inhibited the metastasis of OS cells by suppressing the expression of CD44 ([@b25-ijmm-40-05-1357]). EPH receptor A2 (*EPHA2*) is involved in the mitogenic signaling pathway and it may stimulate OS metastasis ([@b26-ijmm-40-05-1357]). *EPHA2* was identified as a receptor for the targeted drug delivery of OS ([@b27-ijmm-40-05-1357]). High mobility group nucleosomal binding domain 2 (*HMGN2*) exhibits inhibitory effects on growth and migration of human OS cell lines ([@b28-ijmm-40-05-1357]). Yang *et al* found that recurrent LDL receptor-related protein 1 (*LRP1*)-small nuclear ribonucleoprotein U11/U12 subunit 25 (*SNRNP25*) and potassium calcium-activated channel subfamily M regulatory β subunit 4 (*KCNMB4*)-cyclin D3 (*CCND3*) fusion genes promoted tumor cell motility in human OS ([@b29-ijmm-40-05-1357]). The overexpression of cyclin E1 (*CCNE1*) has been observed in many tumors. The inhibition of *CCNE1* suppresses the proliferation of OS cells ([@b30-ijmm-40-05-1357]).

Several featured genes were not reported in the metastasis of OS, while they have been previously shown to be involved in the metastasis of other types of cancer. Histone deacetylase 6 (*HDAC6*) has been shown to be involved in the metastasis of melanoma cells ([@b31-ijmm-40-05-1357]) and oral squamous cell carcinoma (OSCC) cells ([@b32-ijmm-40-05-1357]). The reduced expression of EPH receptor B2 (*EPHB2*) parallels invasion and metastasis in colorectal tumors ([@b33-ijmm-40-05-1357]). The overexpression of the *EPHA4* gene and the reduced expression of the *EPHB2* gene correlate with liver metastasis in colorectal cancer ([@b34-ijmm-40-05-1357]). Cell division cycle 25A (*CDC25A*) regulates matrix metalloprotease 1 through Foxo1 and mediates the metastasis of breast cancer cells ([@b35-ijmm-40-05-1357]). Their roles in OS metastasis remain to be disclosed with further research.

Hypermethylated *ESR1* gene promoter in serum can be used as a candidate biomarker for the diagnosis and treatment efficacy of breast cancer metastasis ([@b36-ijmm-40-05-1357]). The aberrant DNA methylation of ESR1 may be a useful as prognostic indicator in OS ([@b37-ijmm-40-05-1357]). We speculated that it may be involved in OS metastasis. Further studies may provide potential diagnostic biomarkers or therapeutic targets for OS.

In conclusion, in this study, an SVM classifier of high accuracy was obtained with 64 featured genes. Several critical genes associated with OS metastasis were also revealed, some of which are not previously implicated in OS. The findings based on bioinformatics analysis should be further confirmed by experimental studies.

These findings may promote the development of genetic diagnostic methods and may enhance our understanding of the molecular mechanisms underlying the metastais of OS.
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###### 

Information of the gene expression datasets from GEO.

  GEO accession   Platform   Probe no.   Total sample no.   Metastasis   Non-metastasis
  --------------- ---------- ----------- ------------------ ------------ ----------------
  GSE32981        GPL3307    14725       23                 18           5
  GSE21257        GPL10295   48701       53                 34           19
  GSE14359        GPL96      22283       18                 8            10
  GSE14827        GPL570     42450       27                 9            18
  GSE9508         GPL6067    41059       34                 21           13

GEO, Gene Expression Omnibus.

###### 

Quality control test of the gene expression datasets.

  Dataset    IQC    EQC    CQCg     CQCp     AQCg    AQCp    SMR
  ---------- ------ ------ -------- -------- ------- ------- -------
  GSE32981   5.27   3.23   106.65   158.86   32.71   90.88   1.62
  GSE21257   4.38   3.16   64.14    146.51   26.46   96.74   2.86
  GSE14359   4.81   3.23   59.25    171.49   25.5    84.37   2.42
  GSE14827   6.09   1.1    101.1    114.3    19.53   29.46   3.92
  GSE9508    0.23   1.69   6.01     1.58     1.26    0.71    11.58

IQC, internal quality control; EQC, external quality control; CQCg, consistency quality control of genes; CQCp, consistency quality control of pathways; AQCg, accuracy quality control of genes; AQCp, accuracy quality control of pathways; SMR, standardized mean rank.

###### 

Top 10 DEGs ranked by P-value.

  Gene         P-value    Qval       Qpval      τau^2^   Expression
  ------------ ---------- ---------- ---------- -------- ------------
  *C13orf18*   3.20E−05   8.32E−01   8.42E−01   0        \+
  *ATF3*       6.41E−05   1.02E+00   7.97E−01   0        \+
  *CDH5*       6.41E−05   1.82E+00   6.11E−01   0        \+
  *EPHX2*      6.41E−05   1.68E+00   6.42E−01   0        −
  *CDH3*       1.25E−04   2.64E+00   4.51E−01   0        \+
  *ENTPD5*     1.64E−04   1.77E+00   6.21E−01   0        −
  *FOXA1*      1.67E−04   1.80E+00   6.16E−01   0        \+
  *EFNB2*      1.81E−04   2.84E+00   4.17E−01   0        \+
  *BAHD1*      2.10E−04   1.01E+00   7.99E−01   0        −
  *C10orf76*   2.38E−04   2.96E+00   3.98E−01   0        −

\'+\' in the column \'Expression\' indicates upregulation in metastatic OS compared with non-metastatic OS, while \'−\' indicates downregulation in metastatic OS. DEGs, differentially expressed genes; OS, osteosarcoma.

###### 

Top 10 genes ranked by BC.

  Gene      BC         EXP    Degree   P-value    Qval       Qpval      τ^2^
  --------- ---------- ------ -------- ---------- ---------- ---------- ------
  *ESR1*    4.03E−01   −      26       1.60E−02   2.73E+00   4.35E−01   0
  *EP300*   1.90E−01   \+     19       4.86E−02   1.12E+00   7.73E−01   0
  *TP53*    6.70E−02   Null   10       −          −          −          −
  *SMAD3*   1.02E−01   Null   9        −          −          −          −
  *EGFR*    7.40E−02   Null   9        −          −          −          −
  *FN1*     1.33E−01   \+     8        9.80E−03   2.63E+00   4.52E−01   0
  *SRC*     9.92E−02   Null   8        −          −          −          −
  *PRKCA*   8.43E−02   Null   8        −          −          −          −
  *DDX5*    6.33E−02   −      8        1.00E−03   1.04E+00   7.91E−01   0
  *EPOR*    2.35E−02   \+     8        3.80E−02   6.93E−01   8.75E−01   0

\'+\' in the column \'EXP\' indicates upregulation in metastatic OS, while \'−\' indicates downregulation and \'null\' indicates no differential expression. BC, betweenness centrality; OS, osteosarcoma.

###### 

Prediction results of the SVM classifier.

  Datasets   No. of samples   Prediction error   Accuracy   Sensitivity   Specificity   PPV     NPV     AUROC
  ---------- ---------------- ------------------ ---------- ------------- ------------- ------- ------- -------
  GSE21257   53               0                  1.000      1.000         1.000         1.000   1.000   1.000
  GSE32981   23               0                  1.000      1.000         1.000         1.000   1.000   1.000
  GSE14827   27               2                  0.926      1.000         0.889         0.818   1.000   0.931
  GSE14359   18               0                  1.000      1.000         1.000         1.000   1.000   1.000

SVM, support vector machine; PPV, positive predictive value; NPV, negative predictive value; AUROC, area under the ROC curve.

###### 

KEGG pathways significantly over-represented in the 64 featured genes.

  KEGG pathway                                P-value    Genes
  ------------------------------------------- ---------- ------------------------------------------------------
  hsa05200:pathways in cancer                 1.28E−02   *CCNE1, CRKL, EP300, CASP9, BRCA2, BCL2L1, FN1, APC*
  hsa04110:cell cycle                         1.61E−02   *CCNE1, EP300, E2F4, CCND3, CDC25A*
  hsa04360:axon guidance                      1.78E−02   *EPHB6, EFNA1, EFNB2, EPHA2, EPHB2*
  hsa04810:regulation of actin cytoskeleton   2.54E−02   *GIT1, CRKL, BAIAP2, BDKRB2, FN1, APC*
  hsa04350:TGF-β signaling pathway            3.03E−02   *AMH, EP300, E2F4, BMPR2*

KEGG, Kyoto Encyclopedia of Genes and Genomes.

[^1]: Co-first authorship
